CareTrust REIT vs Sabra Health Care REIT
CTRE and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTRE and SBRA compare
CareTrust REIT is the larger company, worth 1.7 times as much as Sabra Health Care REIT ($9.0B against $5.2B).
On earnings, CareTrust REIT is cheaper: it trades at 23.9× trailing earnings, against 73.0× for Sabra Health Care REIT.
CareTrust REIT grew revenue faster over the last twelve months (43.6% versus 23.4% for Sabra Health Care REIT).
CareTrust REIT keeps more of each dollar of sales as profit, with a net margin of 59.2% compared with 7.8% at Sabra Health Care REIT.
Both pay dividends: CareTrust REIT yields 4.0% and Sabra Health Care REIT 7.3%.
CareTrust REIT scores higher on the StockData Score (13 against 6 for Sabra Health Care REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTRE | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $9.0B | $5.2B |
| Share price | $38.07 | $20.44 |
| Change, 1 year | 5.2% | 8.3% |
| Change, 5 years | 84.0% | 43.7% |
| Beta (5Y) | 0.51 | 0.46 |
| Employees | 43 | 58 |
| StockData Score | ||
| Total score | 13 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 4 (better) | 2 |
| Health score | 0 | 0 |
| Dividend score | 3 | 3 |
| Valuation | ||
| P/E | 23.9× (better) | 73.0× |
| P/S | 14.6× | 5.7× (better) |
| P/B | 1.7× (better) | 1.8× |
| EV/EBITDA | 15.6× | 12.7× (better) |
| Fair value | $33.95 | $12.97 |
| Margin of safety | −12.1% (better) | −57.6% |
| Growth | ||
| Revenue growth (TTM) | 43.6% (better) | 23.4% |
| Revenue growth, 5Y average | 21.7% (better) | 5.3% |
| Net income growth (TTM) | 39.3% (better) | −59.2% |
| EPS growth (TTM) | 18.7% (better) | −61.1% |
| EPS growth, 5Y average | 13.1% (better) | −0.91% |
| Profitability | ||
| Net margin | 59.2% (better) | 7.8% |
| Return on equity | 7.8% (better) | 2.5% |
| Financial health | ||
| Altman Z-score | 2.39 (better) | 1.38 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 4.0% | 7.3% (better) |
| Payout ratio | 90.7% | 423% |
| Years of dividend growth | 11 (better) | 0 |
| Dividend growth, 5Y average | 6.0% (better) | −2.3% |
| Buyback yield | −14.9% | – |
| Shareholder yield | −10.9% | 7.3% (better) |
| Ownership | ||
| Held by institutions | 106% | 102% |
| Held by insiders | 0.99% | 1.9% |
| Insider net buying, 12 months | – | −$4.7M |
| Short interest, % of float | 4.0% | 7.1% |
Go deeper
- CTRE stock overview
- CTRE income statement
- CTRE valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.